Mitosis Trumps T Stage and Proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification for Prognostic Value in Resected Stage 1 Lung Adenocarcinoma  by Duhig, Edwina Elizabeth et al.
673Journal of Thoracic Oncology ®  •  Volume 10, Number 4, April 2015
Introduction: We investigated whether a group of pathologists 
could reproducibly apply the International Association for the Study 
of Lung Cancer/American Thoracic Society/European Respiratory 
Society (IASLC/ATS/ERS) classification for lung adenocarci-
noma to a cohort of stage 1 tumors and whether this architectural 
classification and/or other parameters could demonstrate survival 
advantage.
Methods: A total of 145 cases of 7th edition of tumor, node, metas-
tasis stage 1 adenocarcinoma were retrospectively reviewed for pre-
dominant architectural pattern, including cribriform pattern, nuclear 
grade, mitotic index, and necrosis. The parameters were assessed for 
reproducibility and survival and using multivariate analysis, com-
pared with stage, age, and sex.
Results: The majority of tumors had a mixed architecture with the 
acinar pattern being the most common predominant architecture. 
Micropapillary and cribriform architecture were the least frequent 
patterns. This study demonstrated that a group of five patholo-
gists could reproducibly apply the IASLC/ATS/ERS classification. 
Although there were insufficient cribriform-predominant adenocar-
cinomas for assessment, when the percentage of all cribriform was 
combined with other architectures, it was associated with a worse 
prognosis. The majority of the parameters assessed demonstrated sig-
nificance with univariate analysis but only mitotic index, as assessed 
by the highest count/10 high-power fields remained significant with 
multivariate analysis.
Conclusion: In this study of resected stage 1 primary lung adenocar-
cinoma, we found mitotic index to be the only independent prognos-
tic marker. It was more closely associated with outcome than either 
pathologic T stage or IASLC/ATS/ERS architecture-based classifica-
tion. Further validation of concordance and reproducibility in report-
ing mitotic index, as well as validation of prognostic significance, 
needs to be undertaken in independent data sets.
Key Words: Adenocarcinoma, International Association for the Study 
of Lung Cancer/American Thoracic Society/European Respiratory 
Society classification, Cribriform, Mitotic index, Survival, Prognosis
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Recent advances in the management of non–small-cell lung cancer have mandated a review of how patholo-
gists approach the diagnosis of lung cancer. Until recently, 
application of the World Health Organization classification1 
to lung adenocarcinoma resulted in approximately 80% of 
cases being classified as “mixed” subtype, but clinical out-
comes varied widely within this group, and the classification 
held limited prognostic significance.2 There is now evidence 
that adenocarcinoma histologic architecture is of prognostic 
value,3–5 in particular that lepidic-predominant tumors have 
superior survival to those with a solid or micropapillary pat-
tern and that acinar or papillary subtypes have an intermedi-
ate prognosis.5 In 2011, the International Association for the 
Study of Lung Cancer (IASLC), together with the American 
Thoracic Society and the European Respiratory Society, pro-
posed a multidisciplinary classification for lung adenocarci-
noma based on histopathologic architectural subtypes.6 Since 
then, additional studies have validated the reproducibility and 
prognostic value of the classification in independent series,5–13 
although its value in more advanced stages of disease remains 
in doubt.14,15 In an effort to define comprehensive pathologic 
prognostic marker sets, the prognostic value of pathologic 
characteristics other than architecture is increasingly under 
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evaluation. There is evidence that mitotic count16,17 and Ki-67 
labeling18 have value in predicting recurrence of stage 1 ade-
nocarcinoma and that nuclear area and major dimension are 
independent prognostic markers.19
To determine how best to incorporate these various 
histologic markers in a reporting system of prognostic value 
to clinicians, we studied a curated series of resected primary 
lung stage 1 adenocarcinomas. We first assessed implementa-
tion of the 2011 IASLC/American Thoracic Society/European 
Respiratory Society (ATS/ERS) classification by evaluating 
concordance between pathologists’ independent classifica-
tions. We also assessed nuclear grade, mitotic index, necrosis, 
and the new architecture-based IASLC/ATS/ERS classifica-
tion for prognostic value in univariate analyses. Then, to deter-
mine which of these factors had independent prognostic 
significance, multivariate analysis was undertaken with inclu-
sion of recognized prognostic indicators.
METHODS
Following approval by The Prince Charles Hospital 
Ethics Committee, cases of adenocarcinoma resected between 
January 2000 and December 2009 were identified from an 
institutional registry. Tumor slides and pathology reports were 
obtained from the files of Pathology Queensland at The Prince 
Charles Hospital. Lymph node sampling did not strictly accord 
with any protocol; in particular, systematic lymph node dis-
section was not routinely done. For lobectomies, hilar lymph 
nodes were sampled in almost all cases, and targeted mediasti-
nal node sampling was also done based on preoperative imag-
ing. For most sublobar resections, only intrapulmonary lymph 
nodes were sampled. If none of the submitted lymph nodes 
contained adenocarcinoma, the pathologic lymph node stage 
was assigned as N0. Although there were a small number of 
mucinous adenocarcinomas, no other special subtypes were 
included in the cohort. The majority of tumors represented 
the 2004 World Health Organization mixed subtype. The fol-
lowing exclusion criteria were applied to the cases retrieved: 
(1) cases in which examination of records showed evidence 
of known antecedent or concurrent primary adenocarcinoma 
of nonlung origin; (2) cases with multiple primary tumors; 
(3) cases treated with neoadjuvant chemotherapy or radia-
tion therapy; (4) cases for which archived slides could not be 
retrieved; and (5) cases for which 7th edition staging was more 
advanced than stage 1. In the absence of any of these criteria, 
the case was included in the study, and the institutional regis-
try provided prospectively collected demographic, smoking, 
and clinical information.
Application of IASLC/ATS/ERS Classification
IASLC/ATS/ERS classification documents were circu-
lated to five staff anatomical pathologists at The Prince Charles 
Hospital. Examples of architectural patterns specified in the 
classification were identified from cases not included in the 
study series and used for training. Descriptively, lepidic growth 
pattern was defined as growth of neoplastic glandular cells 
along the native alveolar structure of the lung, lacking stromal, 
vascular, or pleural invasion.1,20 Acinar pattern consisted of 
gland formation resembling tubules. Papillary architecture was 
characterized by neoplastic columnar cells lining a fibrovascu-
lar core replacing the underlying lung architecture,1,20 in con-
trast to the lepidic growth pattern that does not fill air spaces. 
In the micropapillary pattern, small tufts of epithelial cells that 
lack fibrovascular cores were present in alveolar spaces or in 
stroma.20 Finally, the solid pattern comprised nests and sheets 
of tumor cells lacking a well-defined glandular pattern.20 The 
percentage of tumor showing cribriform architecture was also 
recorded. This was defined as an individual rounded nest of 
neoplastic cells that contained multiple lumina rather than a 
single lumen tubule of acinar pattern.
Blinded to the original pathology reports, the five pathol-
ogists independently recorded the proportions of all patterns 
(lepidic, acinar, papillary, micropapillary, solid, and cribriform) 
identified within each tumor as a percentage averaged across 
all available slides, rounded to the nearest 5%. For any one pat-
tern, the minimum score was 0% and the maximum was 100% 
(for a tumor with a pure pattern). For each tumor, the median 
percentage of the five pathologists’ scores was calculated for 
each of the architectural patterns. Tumors were then classified 
as predominantly lepidic, acinar, papillary, micropapillary, 
solid, or cribriform according to the architecture with the high-
est median percentage composition. These classifications were 
in turn used to assign differentiation categories: lepidic = well-
differentiated; acinar or papillary = moderately differentiated; 
solid or micropapillary = poorly differentiated. Then, to deter-
mine how best to incorporate cribriform architecture, separate 
analysis was undertaken in which the percentage of cribriform 
architecture assigned by each reader to each tumor was added 
to percentage solid component or alternatively to percent-
age acinar component. Then, the median percentage of each 
architecture was recomputed across all readers, to determine 
the dominant architecture within each tumor. The predominant 
architectures were then combined as described above, and dif-
ferentiation categories were reassigned under each alternative 
(cribriform with solid or cribriform with acinar). Separate sta-
tistical analyses using the two alternative reassigned differenti-
ation grades were then conducted to determine the relationship 
between cribriform architecture and survival.
Assessment of Nuclear Grade, 
Mitotic Count, and Necrosis
The nuclear grading system based on Fuhrman’s crite-
ria and described in the Armed Forces Institute of Pathology 
(AFIP) fascicle on renal tumors21 was circulated to all pathol-
ogists, then applied to the lung adenocarcinomas in this series. 
When assessing nuclear grade, pathologists relied principally 
on nucleolar size, although for nuclear grade 4, two of the 
pathologists also reported using bizarre nuclear shape.
Mitotic activity was assessed by counting the number 
of mitoses within 10 high-power fields (HPF) with the aim of 
counting 50 HPF or five sets of 10 HPF. Pathologists assessed 
the more cellular areas of the tumors for mitosis counts avoid-
ing areas of low cellularity or necrosis. The highest score/10 
HPF was recorded. One pathologist performed mitotic counts 
on all cases in the cohort using a microscope with a high-
power objective diameter of 0.54 mm, and two others (0.55- 
and 0.54-mm high-power objectives) counted a proportion of 
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tumors for confirmation. For statistical assessment, mitotic 
count was divided into four categories: 0 to 5, 5 to 10, 10 to 
20, and more than 20 mitoses/10 HPF, and then, for multi-
variate analysis, mitotic count was categorized as 0 to 10 and 
more than 10 mitoses per 10 HPF.
Necrosis was assessed as present or absent, and the per-
centage of the surface area involved by necrosis was estimated.
Statistical analyses were conducted using SPSS Version 
21 (IBM). A p value of less than 0.05 (two-tailed) was con-
sidered statistically significant in all analyses. To assess con-
cordance between anatomical pathologists, the independently 
assigned histologic architectural patterns were analyzed by 
intraclass correlation, using two-way random analysis for aver-
age measures. Chi-square analysis and analysis of variance 
were used to explore relationships between differentiation, 
nuclear grade, mitosis, and necrosis. Kaplan-Meier survival 
and Cox regression analysis were undertaken for differentia-
tion categories, nuclear grade, mitosis, and necrosis, as well as 
demographic (age and sex) and tumor characteristics (tumor 
size). Multivariate Cox regression analysis was performed, 
using significant covariates from the univariate analyses.
RESULTS
Subjects
A total of 145 cases of IASLC 7th edition stage 1 primary 
lung adenocarcinomas were studied (82 men and 63 women), 
including 14 “never smokers” (fewer than 20 cigarettes ever). 
A total of 125 cases were resected by lobectomy and 20 by 
segmentectomy or wedge procedures. Age at the time of 
resection was 70.5 ± 9.7 years (mean, 1 SD). Sixty-three cases 
were stage 1A (tumor size, <3 cm) and 82 cases were stage 
1B (tumor size, 3–5 cm). Table 1 shows demographic, clinical, 
and pathologic characteristics of the subjects.
IASLC/ATS/ERS Architectural Classification
Intraclass correlation coefficients (ICCs) based on 
average measures showed a high level of concordance 
between pathologists in assignment of architectural clas-
sification (Table 2). Table 2 shows consensus classifica-
tions for the 145 stage 1 adenocarcinomas in this series. 
The acinar pattern was most common, followed by papil-
lary and solid. Micropapillary and cribriform (a pattern not 
recognized by the IASLC/ATS/ERS classification) were the 
least frequent architectures in this series, and there were 
no “pure” examples of these subtypes. Although cribri-
form architecture was observed in 38 cases (26.2%), the 
percentage of cribriform component was 20% or greater 
in only 11. As a sole pattern, it was sufficient to influence 
the assignment of predominant pattern in only three cases. 
However, in determining median predominant pattern for 
each tumor, adding the cribriform proportion to the solid 
proportion (for each reader) resulted in 11 upgrades from 
moderate to poorly differentiated compared with summa-
tion of cribriform and acinar components.
There was no tumor with a pure acinar pattern, but 
examples of pure lepidic, papillary, and solid tumors were 
recorded by the majority of readers. There were 15 pure 
tumors (10%), 28 with two patterns (19%), 45 with three 
patterns (31%), 44 with four patterns (30%), and 13 tumors 
that demonstrated all five IASLC/ATS/ERS patterns (9%). 
When the cribriform pattern was included, there were eight 
pure tumors (5.5%), 25 with two patterns (17.2%), 46 with 
three patterns (31.7%), 44 with four patterns (30.3%), 19 
with five patterns (13.1%), and three with six patterns (2.1%) 
(Supplementary Table 1, Supplementary Digital Content 1, 
http://links.lww.com/JTO/A764). The median number of 
IASLC/ATS/ERS patterns observed within tumors that were 
well or moderately differentiated overall was three, while 
poorly differentiated tumors contained a median of two 
architectural patterns.
Analysis of Nonarchitectural Prognostic Factors
Nuclear grade 
The ICC for average measures of nuclear grade as used 
in renal carcinoma indicated high concordance when patholo-
gists applied it to lung adenocarcinomas: ICC, 0.804 (95% 
confidence interval [CI], 0.748–0.850; p < 0.0001). No cases 
were assigned nuclear grade 1. As expected, tumors with 
lepidic-predominant pattern had a lower nuclear grade than 
those with higher grade architectural patterns (chi-square sta-
tistic = 56.5; p < 0.0001; Table 2).
Mitotic count
Although only one pathologist assessed all tumors, 
two others examined a proportion of the cases with excellent 
inter-reader agreement: ICC, 0.944 (95% CI, 0.875–0.978; p 
< 0.0001). Mitoses per 10 HPF ranged from 0 to 71, mean 
11.6 ± 11 (1 SD) in the whole group, 0 to 5 in 38.6%, 5 to 10 
in 18.6%, and more than 10 in 42.7% of tumors. There was a 
significant association between two-tier mitotic grade strati-
fied at 10 mitoses per 10 HPF and grade of differentiation 
(Fisher’s exact test, 28.9; p < 0.0001; Table 2).
TABLE 1.  Clinical and Demographic Characteristics of 145 
Cases of Stage 1 Primary Lung Adenocarcinoma
Number Percent
Median 
(Range)
Mean  
(1 SD)
Age (yr) 70.5 (9.7)
Gender
  Males 82 56.6
  Females 63 43.4
Resection type
  Lobectomy 125 86.3
  Segmental or subsegmental 20 13.8
7th edition stage
  Stage T1a (1A) 25 17.2
  Stage T1b (1A) 38 26.2
  Stage T2a (2A) 82 56.5
Smoking
  Never smokers 14 9.7
  <10 pack years 5 3.4
  ≥10 pack years 126 86.9
  Pack years (n = 131 
smokers)
45 (1–135)
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Necrosis
Although only one pathologist assessed all tumors for 
necrosis, two others examined a proportion of the tumors, 
with high concordance indicated by the ICC 0.95 (95% CI, 
0.891–0.981; p < 0.0001). Necrosis (including focal areas) 
was present in 72 of 145 adenocarcinomas. The percentage of 
necrosis increased with grade of differentiation: 2.4% ± 0.5% 
in moderately differentiated and 14.3% ± 2.0% in poorly dif-
ferentiated tumors, with no lepidic predominant adenocarci-
noma showing any degree of necrosis.
Associations between prognostic indicators. 
Mitotic count, nuclear grade, and presence or absence 
of necrosis were all closely associated with grade of differ-
entiation based on IASLC/ATS/ERS architectural patterns 
(Fisher’s exact test values 28.9, 33.6, and 47.1, respectively, 
p < 0.0001 for all). Tumor size (pT stage, 7th edition IASLC) 
was not significantly associated with mitotic count, nuclear 
grade, necrosis, or architectural pattern in this series.
Survival Analyses
Overall survival for the patients in this series of resected 
stage 1 only adenocarcinomas was mean 7.1 years (95% CI, 
6.4–7.8) and median 9.2 years (95% CI, 6.4–12.0). Mean and 
median survivals for females were 7.7 and 9.2 years, respec-
tively, in contrast to males’ 6.6 and 6.7 years. There was no 
significant difference in survival between men and women (log-
rank test, p = 0.11) nor between cases younger or older than the 
median age (7.1 vs. 7.0 yr, p = 0.87). As expected, subjects with 
stage 1A tumors (7th edition) survived longer than those with 
stage 1B tumors: mean 8.1 years (95% CI, 7.1–9.0) compared 
with 6.2 years (95% CI, 5.4–7.0; p = 0.03 by log-rank test). 
Tumors 2 cm or smaller in diameter were associated with longer 
survival than those between 3 and 5 cm (mean, 7.8 yr vs. 5.8 yr; 
p < 0.05). Whether tumor size was measured (total tumor diam-
eter) or estimated from the invasive component, the observed 
survival difference was similar. Survival was not significantly 
different between tumors up to 2 cm and those between 2 and 
3 cm nor between tumors 3 and 5 cm in diameter and those 
between 2 and 3 cm (Supplementary Fig. 1, Supplementary 
Digital Content 2, http://links.lww.com/JTO/A765).
Survival differed according to tumor architectural pat-
terns classified by the IASLC/ATS/ERS system (p = 0.048; 
Fig. 1A) and according to grade of differentiation assigned 
from architectural patterns excluding cribriform (p = 0.012; 
Fig. 1B). Assignment of cribriform with the solid pattern 
reclassified 12 cases (11 upgrades between moderate and 
poor) resulting in greater divergence between the survival 
curves of moderate and poorly differentiated tumors than 
when cribriform pattern was assigned with acinar (Fig. 2).
Survival also differed significantly with nuclear grade 
(p = 0.012; Fig. 3A) and necrosis (mean, 8.4 yr without necro-
sis; 5.9 yr with any degree of necrosis; p < 0.001; log-rank 
test; Fig. 3B).
A threshold of five mitoses/10 HPF was previ-
ously reported to separate adenocarcinoma into prognostic 
groups,16,17 tumors with a mitotic count of more than 5/10 HPF 
having significantly worse survival than tumors with 0 to 5 
mitoses/10 HPF. We initially examined survival at four levels 
of mitotic count: 0 to 5, 5 to 10, 10 to 20, and more than 20 per 
10 HPF. This analysis showed that the clearest survival differ-
ences occurred between tumors with mitosis counts above and 
below 10 mitoses per 10 HPF (p < 0.0001; Fig. 4).
Multivariate Analysis
To determine which factors were independently prognos-
tic for survival, multivariate analysis was undertaken. Age and 
TABLE 2.  Concordance and Classification by Architecture, Differentiation, Nuclear Grade, and Mitosis Count of 145 Stage 1 
Primary Lung Adenocarcinomas
Predominant Architecture Lepidic Acinar Papillary Micropapillary Solid Total
n (%) 10 (6.9) 64 (44.1) 33 (22.8) 1 (0.7) 37 (25.5) 145
Concordance (intraclass 
correlation coefficients)
0.94 0.88 0.90 0.85 0.98 p < 0.0001, all
Differentiation Well Moderate Poor
n (%) 10 (6.9) 97 (66.9) 38 (26.2) 145
Necrosis
  Absent 10 60 3 73
  Present (≥1%) 0 37 35 72 χ2 = 42.4, p < 0.0001
Nuclear grade
  2 6 4 0 10
  3 4 52 12 68
  4 0 41 26 67 χ2 = 56.5, p < 0.0001
Mitosis count
  0–10/10 HPF 10 64 9 83
  >10/10 HPF 0 33 29 62 Fisher’s exact  
test = 28.9,  
p < 0.0001
Concordance was assessed by computing intraclass correlation coefficients for average measures of five pathologists. Mitosis count is maximum, per 10 HPF of 50 HPF counted.
HPF, high-power field.
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sex were included in the model, as well as the factors that were 
significant in univariate analysis of survival including IASLC/
ATS/ERS adenocarcinoma classification, stage, mitotic count, 
necrosis, and nuclear grade. The only factor retaining signifi-
cance in multivariate analysis was two-tier mitotic count strati-
fied at 10/10 HPF (p = 0.001; Table 3). The analysis shows that 
the hazard of death for cases with tumor mitosis counts above 
10/10 HPF was 4.6 times that of cases with tumor mitosis counts 
of less than 10/10 HPF (95% confidence limits, 1.9–11.1).
Mitosis count was significantly prognostic for survival 
within each stratum of pathologic T stage and within each 
grade of differentiation classified by the IASLC/ATS/ERS 
system (Fig. 5).
DISCUSSION
In a curated case series of resected stage 1 adenocar-
cinoma, mitotic count was the only independent prognostic 
FIGURE 1.  Prognostic significance of tumor architecture and differentiation in stage 1 adenocarcinoma. A, Survival stratified by 
predominant architectural pattern (log-rank p = 0.048). B, Survival stratified by grade of differentiation (log-rank p = 0.012).
FIGURE 2.  Prognostic significance of cribriform pattern. When the cribriform pattern was included with the solid component 
in assignment of differentiation (A), the survival difference between moderate and poorly differentiated tumors was greater (log-
rank Mantel Cox, chi-square, 9.2; p = 0.002) than when cribriform pattern was included with acinar (B) (log-rank Mantel Cox, 
chi-square, 4.2; p = 0.04).
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factor for survival. Mean survival time for tumors with up 
to 10 mitoses per 10 HPF was 8.93 years (95% CI, 8.2–9.6) 
(median not reached in this analysis), compared with 5.2 years 
(95% CI, 4.3–6.1) for tumors with more than 10 mitoses per 
10 HPF. If prospectively validated, this could have implica-
tions for adjuvant management and follow-up of resected 
stage 1 lung adenocarcinoma.
Although not currently a recommended component of 
standardized reporting of resected lung cancer, determination 
of mitotic count requires no additional stains or sections, is 
within the capabilities of any pathology service, and (in our 
hands) has high inter-reader concordance. Mitotic count was 
not correlated with stage or tumor size, but it was significantly 
associated with differentiation grade and architectural pat-
terns. However, the prognostic utility of mitotic index was 
retained within each class of differentiation, clearly separat-
ing moderately differentiated tumors into those with better 
and worse survival, and similarly for poorly differentiated 
tumors. This did not apply to lepidic pattern tumors, none 
of which had a high mitotic rate, and for which survival was 
excellent. In this series of resected stage 1 adenocarcinomas 
tumor, mitotic rate had prognostic utility superior to both T 
stage and the IASLC/ATS/ERS architecture-based differentia-
tion classification.
The value of volume doubling time has long been rec-
ognized in assessing natural history, but models of tumor 
growth are still not sufficiently accurate to predict outcomes 
from tumor volume doubling time.21 Ki-67 labeling index was 
found to be a statistically significant prognostic factor for dis-
ease-free survival in non–small-cell lung cancer after video 
assisted thoracoscopy segmentectomy.18 Kadota et al17 dem-
onstrated a significant association between mitotic count and 
histology grade, Ki-67 proliferative index, and recurrence-
free probability, and they concluded that mitotic count was 
the single most important predictor of recurrence in patients 
with stage 1 lung adenocarcinoma. The studies by Kadota et 
al17 and von der Thüsen et al16 both used a threshold of an 
average five mitoses per 10 HPF. In contrast, we assessed the 
highest number of mitoses per 10 HPF from counts of 50 
HPF. In our data, it was clearly demonstrated that 10 mito-
ses per 10 HPF was the optimum cutpoint for distinguish-
ing survival outcomes. It is noted Xu et al22 found that more 
than one mitosis per HPF was independently associated with 
FIGURE 3.  Prognostic significance of nuclear grade and necrosis. A, Survival stratified by nuclear grade (modified from 
Fuhrman’s criteria: grades 2, 3, and 4) (log-rank p = 0.012). B, Survival stratified by necrosis. Any degree of necrosis was associ-
ated with poorer survival (log-rank p ≤ 0.001).
FIGURE 4.  Survival stratified by Mitosis count. Survival 
stratified by mitosis counts showed clear divergence with sta-
tistically poorer survival for tumors with mitosis counts above 
10/10 high-power fields (log-rank p < 0.0001).
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metastasis. If mitosis counts are to be useful prognostically, 
further analysis to optimize cutpoints is needed.
Our data show that the IASLC/ATS/ERS classification 
can be applied with a high degree of concordance between 
pathologists with varying levels of experience. However, all 
pathologists contributing to this study were working within 
the same department, so this could to some degree reflect 
intradepartmental training and shared experience. A group of 
internationally recognized pathologists previously reported 
that classic architectural patterns could be identified with high 
concordance,23 but the ability to distinguish in situ (lepidic) 
from invasive (usually papillary) carcinoma was only fair. 
Importantly, specific training leads to acceptable interobserver 
variation24 and improves concordance,25 but these studies 
TABLE 3.  Multivariate Analysis
B SE p Hazard Ratio
95% Confidence Interval 
for Hazard Ratio
Lower Upper
Sex (0 = male, 1 = female) −0.606 0.359 0.091 0.545 0.270 1.101
Age (0 = below median, 1 = above median) −0.071 0.322 0.826 0.932 0.495 1.753
Stage (7th edition) (0 = 1A, 1 = 1B) 0.181 0.355 0.610 1.199 0.598 2.403
Nuclear grade (0 = grade 2 or 3, 1 = grade 4) 0.354 0.355 0.318 1.425 0.711 2.858
Necrosis (0 = 0%, 1 = 1% or greater) 0.333 0.406 0.412 1.395 0.629 3.090
Mitosis count (0 = 0–10 per 10 HPF, 1 ≥ 10 per 10 HPF) 1.523 0.452 0.001 4.585 1.893 11.110
Differentiation (0 = moderate/well, 1 = poor) −0.027 0.357 0.940 0.973 0.484 1.959
Multivariate Cox regression analysis entering age, sex, and the significant covariates from univariate analyses (all as dichotomous variables).
B, regression coefficient; SE, standard error; hazard ratio, risk of death for prognostic variables (category 1 vs. category 0); HPF, high-power field.
FIGURE 5. A, Mitosis count is prognostic for stage 1 primary lung adenocarcinoma within each pathologic T stage subgroup. 
Log-rank test of equality of distributions of the two tiers of Mitosis count (<10 and ≥10) showed chi-square values of 8.3 
(p = 0.004) for stage pT1a, 19.0 (p < 0.0001) for pT1b, and 4.4 (p = 0.035) for pT2a. B, Mitosis count is prognostic for stage 1 
primary lung adenocarcinoma within each International Association for the Study of Lung Cancer/American Thoracic Society/
European Respiratory Society differentiation class. Log-rank test of equality of distributions of the two tiers of mitotic index (<10 
and ≥10/10 high-power fields) showed chi-square values of 15.2 (p < 0.0001) for moderately differentiated tumors and 3.9 
(p = 0.049) for poorly differentiated tumors.
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emphasize the need for more precise definitions of architec-
tural patterns. We observed a significant association between 
survival and tumor architecture, but in multivariate analysis, 
the prognostic value of tumor architecture was not indepen-
dent of mitotic rate. Multiple groups5–13 have now demon-
strated that stage 1 lung adenocarcinomas can be stratified 
prognostically using IASLC/ATS/ERS architectural patterns, 
but some have found the classification of limited prognostic 
significance in advanced stage disease and recommended 
further evaluation of other prognostic factors before appli-
cation of the classification to unselected surgically resected 
adenocarcinomas.15
Although a common architectural pattern in breast, large 
intestine, and prostate adenocarcinomas, the cribriform pattern 
was uncommon and the least reproducible architectural pat-
tern in this series of lung adenocarcinomas, and it was associ-
ated with a poorer prognosis. Cribriform structures in prostate 
carcinoma are now considered higher grade than acinar struc-
tures and are included in the Gleason 4 group.26 The cribriform 
architectural pattern was included as a form of acinar adeno-
carcinoma in the 2011 IASLC/ATS/ERS classification,20 rather 
than as a separate pattern. Although some have suggested that 
it be included with the acinar pattern,27 other studies of the sig-
nificance of cribriform pattern in lung adenocarcinoma dem-
onstrate that it is associated with poor prognosis,28 higher risk 
of recurrence, lymph node metastases,22 lymphovascular inva-
sion, increased mitotic activity, and more advanced stage dis-
ease.29 There is residual uncertainty about the significance of 
cribriform architecture in lung adenocarcinoma with proposals 
for a separate additional architecture30 or alternatively includ-
ing it as a solid architecture, as we undertook.
In this study, we adapted the nuclear grading scheme 
in common usage for renal cell carcinoma to lung adenocar-
cinoma and found that, as in breast and kidney malignancies, 
low nuclear grade was associated with survival advantage in 
lung adenocarcinoma in univariate analysis, but this was not 
borne out in multivariate analysis. We found this to be simple 
and reproducible. Apart from a small number of tumors at the 
better differentiated end of the spectrum, nearly all were clas-
sified as nuclear grade 3 or 4, suggesting that a simple two-tier 
system for nuclear grading could be applied to lung adeno-
carcinoma. Other studies of the prognostic significance of 
nuclear grade in lung adenocarcinoma report variable results, 
including no significant relationship between nuclear grade 
and survival,16 significance only in univariate analysis,17 or 
significance in multivariate analysis.31
The evidence for the IASLC/ATS/ERS grading scheme 
was based on surgically resected tissue, but only approxi-
mately 20% to 30% of all lung adenocarcinoma patients have 
resectable disease. Therefore, the classification may not have 
the same prognostic significance in unresectable disease. 
Architectural patterns displayed within individual tumors 
are multiple and heterogeneous, with approximately 70% 
of resected adenocarcinomas in this study displaying three 
or more architectural patterns. Because representation of 
these patterns within small diagnostic biopsies is likely to be 
restricted, differentiation grading based on small biopsies is 
expected to be far less accurate than when based on resection 
specimens. Improved methods of grading diagnostic samples 
are needed.
For similar reasons, although mitotic rate was the sin-
gle independent prognostic marker in this series of resected 
stage 1 adenocarcinomas, counting large numbers of HPFs 
in small biopsy specimens will be difficult. Related indices 
of tumor cell turnover such as Ki-67 proliferative index may 
prove more reliable in small samples. Meanwhile, immediate 
treatment decisions will continue to rely on stage as the major 
determinant of management.
In conclusion, in this study of resected stage 1 primary 
lung adenocarcinoma, we found mitotic count to be the only 
independent prognostic marker for survival. It was more 
closely associated with outcome than either pathologic T stage 
or IASLC/ATS/ERS architecture-based classification. Further 
validation of concordance and reproducibility in reporting 
mitotic index, as well as of its prognostic significance in inde-
pendent data sets, is needed. Applicability to more advanced 
stage resected adenocarcinomas should be investigated, and 
further evaluation of markers of cell turnover in small diag-
nostic samples is also needed. Pending confirmation of our 
findings in larger independent studies we propose that mito-
sis counts be incorporated into pathology reports of resected 
stage 1 adenocarcinoma of lung.
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